4,7-Diazaspiro[2.5]octan-7-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4,7-Diazaspiro[2.5]octan-7-amine
• 英文别名: 4,7-diazaspiro[2.5]octan-7-amine
• 化学式: C₆H₁₃N₃
• 分子量: 127.19
• InChiKey: RVICAUNPYUMVDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] NOVEL COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION<br/>[FR] NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DE MALADIES LIÉES À L'EXPRESSION DE DUX4
  申请人：FACIO INTELLECTUAL PROPERTY B V

  公开号：WO2021105481A1

  公开（公告）日：2021-06-03

  The present invention relates to compounds that act as DUX4 repressors, suitable for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.

  本发明涉及作为DUX4抑制剂的化合物，适用于治疗与DUX4表达相关的疾病，如肌肉萎缩症。它还涉及使用这些化合物，或者使用这些化合物的方法。
• [EN] NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION<br/>[FR] NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DE MALADIES LIÉES À L'EXPRESSION DE DUX4
  申请人：FACIO INTELLECTUAL PROPERTY B V

  公开号：WO2021105474A1

  公开（公告）日：2021-06-03

  The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.

  本发明涉及用于治疗与DUX4表达相关疾病的化合物，如肌肉萎缩症。它还涉及使用这些化合物，或者使用这些化合物的方法。
• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014135495A1

  公开（公告）日：2014-09-12

  The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

  本发明公开了化合物的结构式I：其中结构式I中的变量如本文所述。还公开了含有这些化合物的药物组合物，以及使用结构式I中的化合物预防或治疗HCV感染的方法。
• [EN] COMBINATION THERAPY FOR SPINAL MUSCULAR ATROPHY<br/>[FR] POLYTHÉRAPIE POUR ATROPHIE MUSCULAIRE SPINALE
  申请人：BIOGEN MA INC

  公开号：WO2021030766A1

  公开（公告）日：2021-02-18

  Aspects of the application relate to compositions and methods for treating spinal muscular atrophy in a subject. In particular, this application provides therapeutic combinations of a small molecule that promotes SMN function and/or a recombinant nucleic acid that encodes the survival of motor neuron 1 (SMN1) protein (e.g., in a viral vector), and/or an antisense oligonucleotide (ASO) that increases full-length survival of motor neuron 2 (SMN2) mRNA (e.g., that is targeted to a nucleic acid molecule encoding the survival of motor neuron 2 (SMN2) and promotes the inclusion of exon 7 in SMN2 mRNA).